Reply to Non–coding RNAs, osteoarthritis and the microbiome: new therapeutic targets?

2021 ◽  
Author(s):  
Jie Wei ◽  
Yuqing Zhang ◽  
Chao Zeng ◽  
Guanghua Lei
Keyword(s):  
Therapeutic Targets ◽  
Non Coding Rnas ◽  
New Therapeutic Targets

scholarly journals Functional Screening Techniques to Identify Long Non-Coding RNAs as Therapeutic Targets in Cancer

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3695
Author(s):  
Kathleen M. Lucere ◽  
Megan M. R. O’Malley ◽  
Sarah D. Diermeier
Keyword(s):  
Antisense Oligonucleotides ◽  
High Throughput Screening ◽  
Large Scale ◽  
Therapeutic Targets ◽  
Functional Screening ◽  
Protein Coding ◽  
Non Coding Rnas ◽  
New Therapeutic Targets ◽  
Functional Screens ◽  
Screening Approaches

Recent technological advancements such as CRISPR/Cas-based systems enable multiplexed, high-throughput screening for new therapeutic targets in cancer. While numerous functional screens have been performed on protein-coding genes to date, long non-coding RNAs (lncRNAs) represent an emerging class of potential oncogenes and tumor suppressors, with only a handful of large-scale screens performed thus far. Here, we review in detail currently available screening approaches to identify new lncRNA drivers of tumorigenesis and tumor progression. We discuss the various approaches of genomic and transcriptional targeting using CRISPR/Cas9, as well as methods to post-transcriptionally target lncRNAs via RNA interference (RNAi), antisense oligonucleotides (ASOs) and CRISPR/Cas13. We discuss potential advantages, caveats and future applications of each method to provide an overview and guide on investigating lncRNAs as new therapeutic targets in cancer.

scholarly journals Non-Coding RNAs as New Therapeutic Targets in the Context of Renal Fibrosis

2019 ◽  
Vol 20 (8) ◽  
pp. 1977 ◽  
Author(s):  
Cynthia Van der Hauwaert ◽  
François Glowacki ◽  
Nicolas Pottier ◽  
Christelle Cauffiez
Keyword(s):  
Renal Fibrosis ◽  
Molecular Mechanisms ◽  
Tissue Injury ◽  
Kidney Diseases ◽  
Therapeutic Targets ◽  
Future Research ◽  
Kidney Fibrosis ◽  
Extracellular Matrix Components ◽  
Non Coding Rnas ◽  
New Therapeutic Targets

Fibrosis, or tissue scarring, is defined as the excessive, persistent and destructive accumulation of extracellular matrix components in response to chronic tissue injury. Renal fibrosis represents the final stage of most chronic kidney diseases and contributes to the progressive and irreversible decline in kidney function. Limited therapeutic options are available and the molecular mechanisms governing the renal fibrosis process are complex and remain poorly understood. Recently, the role of non-coding RNAs, and in particular microRNAs (miRNAs), has been described in kidney fibrosis. Seminal studies have highlighted their potential importance as new therapeutic targets and innovative diagnostic and/or prognostic biomarkers. This review will summarize recent scientific advances and will discuss potential clinical applications as well as future research directions.

Therapeutic Targets for the Treatment of Comorbidities Associated with Epilepsy

2020 ◽  
Vol 13 (2) ◽  
pp. 85-93
Author(s):  
Kinjal Gangar ◽  
Lokesh Kumar Bhatt
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Attention Deficit ◽  
Neurological Disorders ◽  
Therapeutic Targets ◽  
Therapeutic Failure ◽  
Hyperactivity Disorder ◽  
Novel Targets ◽  
New Therapeutic Targets ◽  
Dual Mechanism ◽  
Seizure Suppression

One of the most common neurological disorders, which occurs among 1% of the population worldwide, is epilepsy. Therapeutic failure is common with epilepsy and nearly about 30% of patients fall in this category. Seizure suppression should not be the only goal while treating epilepsy but associated comorbidities, which can further worsen the condition, should also be considered. Treatment of such comorbidities such as depression, anxiety, cognition, attention deficit hyperactivity disorder and, various other disorders which co-exist with epilepsy or are caused due to epilepsy should also be treated. Novel targets or the existing targets are needed to be explored for the dual mechanism which can suppress both the disease and the comorbidity. New therapeutic targets such as IDO, nNOS, PAR1, NF-κb are being explored for their role in epilepsy and various comorbidities. This review explores recent therapeutic targets for the treatment of comorbidities associated with epilepsy.

Sign in / Sign up

Export Citation Format

Share Document